24/7 Market News Snapshot 17 June, 2025 – Immuneering Corporation Class A Common Stock (NASDAQ:IMRX)

June 17, 2025

DENVER, Colo., 17 June, 2025 (www.247marketnews.com) – (NASDAQ:IMRX) are discussed in this article.
Immuneering Corporation is experiencing significant momentum in the pre-market trading session, with its Class A Common Stock (IMRX) priced at $2.892, representing an impressive increase of 22.03% from the prior close of $2.370. This surge comes alongside a robust trading volume of 2.71 million shares, indicating heightened investor confidence and interest in the biotechnology sector. Technical analyses suggest the potential for continued upward movement, prompting investors to remain vigilant as opportunities evolve within this dynamic market.

In addition to its trading performance, Immuneering has announced promising results from its ongoing Phase 2a clinical trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients. The trial has achieved an extraordinary 94% overall survival (OS) rate at six months and a 72% progression-free survival (PFS) rate among participants. Ben Zeskind, Ph.D., the company’s Co-founder and CEO, expressed enthusiasm over these findings, emphasizing the potential of atebimetinib to significantly enhance survival outcomes for patients dealing with advanced pancreatic cancer.

The trial, which included 34 patients, recorded a notable 39% overall response rate and an 81% disease control rate, with many participants experiencing substantial and lasting improvements. Notably, atebimetinib was highlighted for its favorable tolerability profile, as no Grade 3 or higher adverse events were reported—a positive indicator for the future of cancer therapy.

Looking ahead, Immuneering plans to initiate a pivotal trial of atebimetinib in conjunction with mGnP for treating first-line pancreatic cancer by 2026, following anticipated regulatory feedback in late 2025. The company is also focused on expanding patient enrollment to approximately 50 participants within the ongoing study, further reinforcing its commitment to advancing treatment options for this challenging disease. As Immuneering continues on this upward trajectory, its innovations signal a hopeful path forward for pancreatic cancer therapies.

Related news for (IMRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.